Lilly Sees 2022 Profit Above Estimates on Boost From Potential New Drugs

Eli Lilly on Wednesday forecast 2022 profit above Wall Street estimates as it bets on new drug approvals to counter the impact of competition and pricing pressures on its other key treatments, sending its shares up nearly 10%. Read More